Furthermore, they speculated that lowPDS5B-expressing tumors are more responsive to DNA damagingchemotherapy [71].RFC3 copy number gains are frequently found in colon and oesophagealcancers, and in the latter cancer, Lockwood and colleagues showed thatRFC3 knockdown inhibited proliferation and anchorage-independentgrowth [72]. This evidence concerns the gene RFC3 and cancer.